{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:23:40Z","timestamp":1789035820069,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>As commercially available pregabalin preparations are limited to oral administration, it is impossible to use it as an adjuvant analgesic for neuropathic cancer-related pain in terminally ill cancer patients with oral feeding difficulties. The objective of this study was to develop a pregabalin suppository to be available at hospitals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pregabalin suppositories were prepared using bases comprising six different compositions of Witepsol H-15, Witepsol S-55, and Witepsol E-75. The suppository release test and stability test were performed in vitro. The pharmacokinetics and pharmacodynamics of the suppositories were assessed in rats.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>In the in vitro releasing test, the pregabalin suppositories with H-15, H-15 : S-55 = 1 : 1, H-15 : S-55 = 2 : 1, H-15 : S-55 = 1 : 2 released approximately 100% of the pregabalin within 180 min. Among these pregabalin suppositories, only the suppository with H-15 : S-55 = 2 : 1 demonstrated an equivalent AUC0\u2212\u221e with the oral administration group. Consistent with the results of the pharmacokinetic study, the pregabalin suppository with H-15 : S-55 = 2 : 1 exhibited antinociceptive effects. In addition, the pregabalin suppository with H-15 : S-55 = 2 : 1 was stable for 12 weeks when refrigerated with light shielding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The pregabalin suppositories prepared in this study may be applicable for pain control for terminally cancer ill patients with oral feeding difficulties.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jphp.13051","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T23:19:07Z","timestamp":1543965547000},"page":"746-752","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetic and pharmacodynamic studies of pregabalin suppositories based on pharmacological research"],"prefix":"10.1093","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1128-7740","authenticated-orcid":false,"given":"Ryo","family":"Yajima","sequence":"first","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , Tokyo,","place":["Japan"]},{"name":"Section\u00a0of Pharmaceutical Services, Nippon Medical School Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Yokono","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Watabe","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Enoki","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Keio University Faculty of Pharmacy , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Ise","sequence":"additional","affiliation":[{"name":"Section\u00a0of Pharmaceutical Services, Nippon Medical School Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Katayama","sequence":"additional","affiliation":[{"name":"Section\u00a0of Pharmaceutical Services, Nippon Medical School Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Kizu","sequence":"additional","affiliation":[{"name":"Pharmaceutical Common Achievement Tests Organization , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,1]]},"reference":[{"key":"2024103012315597400_jphp13051-cit-0001","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1533-2500.2011.00485.x","article-title":"Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature","volume":"12","author":"Vadalouca","year":"2012","journal-title":"Pain Pract"},{"key":"2024103012315597400_jphp13051-cit-0002","first-page":"216","article-title":"Breast cancer pain management \u2013 a review of current & novel therapies","volume":"139","author":"Satija","year":"2014","journal-title":"Indian J Med Res"},{"key":"2024103012315597400_jphp13051-cit-0003","doi-asserted-by":"crossref","first-page":"861","DOI":"10.5649\/jjphcs.41.861","article-title":"Characterization of pharmacokinetic parameters for hospital preparation of suppository containing gabapentin tablet","volume":"41","author":"Arai","year":"2015","journal-title":"J Pharm Health Care Sci"},{"key":"2024103012315597400_jphp13051-cit-0004","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0885-3924(05)80021-1","article-title":"Character of terminal illness in the advanced cancer patients: pain and other symptoms during the last four weeks of life","volume":"5","author":"Coyle","year":"1990","journal-title":"J Pain Symptom Manage"},{"key":"2024103012315597400_jphp13051-cit-0005","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/j.euroneuro.2006.04.005","article-title":"Pregabalin: from molecule to medicine","volume":"16","author":"Kavoussi","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"key":"2024103012315597400_jphp13051-cit-0006","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/syn.10094","article-title":"Preferential action of gabapentin and pregabalin at P\/Q-type voltage-sensitive calcium channels: inhibition of K + -evoked [3H]-norepinephrine release from rat neocortical slices","volume":"45","author":"Dooley","year":"2002","journal-title":"Synapse"},{"key":"2024103012315597400_jphp13051-cit-0007","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1523\/JNEUROSCI.0356-09.2009","article-title":"The increased trafficking of the calcium channel subunit\u03b12\u03b4-1 to presynaptic terminals in neuropathic pain is inhibited by the \u03b12\u03b4 ligand pregabalin","volume":"29","author":"Bauer","year":"2009","journal-title":"J Neurosci"},{"key":"2024103012315597400_jphp13051-cit-0008","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2174\/138945009788982513","article-title":"Gabapentin and pregabalin for the acute post-operative pain management. A systematic-narrative review of the recent clinical evidences","volume":"10","author":"Dauri","year":"2009","journal-title":"Curr Drug Targets"},{"key":"2024103012315597400_jphp13051-cit-0009","first-page":"1381","article-title":"The appropriate use of adjuvant analgesics for neuropathic cancer pain","volume":"46","author":"Isebaba","year":"2010","journal-title":"Jpn Soc Hosp Pharm"},{"key":"2024103012315597400_jphp13051-cit-0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejphar.2014.08.030","article-title":"Pregabalin role in inhibition of morphine analgesic tolerance and physical dependency in rats","volume":"742","author":"Hasanein","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"2024103012315597400_jphp13051-cit-0011","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40780-016-0063-6","article-title":"Pregabalin prescription for terminally ill cancer patients receiving specialist palliative care in an acute hospital","volume":"2","author":"Yajima","year":"2016","journal-title":"J Pharm Health Care Sci"},{"key":"2024103012315597400_jphp13051-cit-0012","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40780-016-0055-6","article-title":"Pharmaceutical studies on and clinical application of olanzapine suppositories prepared as a hospital preparation","volume":"2","author":"Matsumoto","year":"2016","journal-title":"J Pharm Health Care Sci"},{"key":"2024103012315597400_jphp13051-cit-0013","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejpb.2006.06.004","article-title":"Reciprocating dialysis tube method: periodic tapping improved in vitro release\/dissolution testing of suppository","volume":"64","author":"Itoh","year":"2006","journal-title":"Eur J Pharm Biopharm"},{"key":"2024103012315597400_jphp13051-cit-0014","doi-asserted-by":"crossref","first-page":"714","DOI":"10.5649\/jjphcs.41.714","article-title":"A comparison of the solubility and divisibility of commercial acetaminophen suppository","volume":"41","author":"Kuroda","year":"2015","journal-title":"J Pharm Health Care Sci"},{"key":"2024103012315597400_jphp13051-cit-0015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.saa.2008.08.009","article-title":"Spectrophotometric and spectrofluorimetric methods for the determination of pregabalin in bulk and pharmaceutical preparation","volume":"72","author":"Onal","year":"2009","journal-title":"Spectrochim Acta A"},{"key":"2024103012315597400_jphp13051-cit-0016","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jchromb.2014.05.030","article-title":"Simultaneous determination of gabapentin, pregabalin, vigabatrin, and topiramate in plasma by HPLC with fluorescence detection","volume":"962","author":"Martinc","year":"2014","journal-title":"J Chromatogr B"},{"key":"2024103012315597400_jphp13051-cit-0017","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0022-3565(25)03823-6","article-title":"A method for determining loss of pain sensation","volume":"72","author":"D'Amour","year":"1941","journal-title":"J Pharmacol Exp Ther"},{"key":"2024103012315597400_jphp13051-cit-0018","first-page":"349","article-title":"Pharmacokinetic analysis of rectal absorption piroxicam in rats","volume":"14","author":"Kobayashi","year":"1984","journal-title":"Kitasato Med"},{"key":"2024103012315597400_jphp13051-cit-0019","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1023\/A:1018933916331","article-title":"Modification of the dialysis membrane method for drug release from suppository","volume":"10","author":"Yamazaki","year":"1993","journal-title":"Pharm Res"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.13051","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jphp.13051","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jphp.13051","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/71\/5\/746\/60224037\/jphp13051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/71\/5\/746\/60224037\/jphp13051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T09:05:46Z","timestamp":1775293546000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/71\/5\/746\/6121984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,1]]},"published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.13051","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"value":"2042-7158","type":"electronic"},{"value":"0022-3573","type":"print"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2019,5,1]]}}}